KZIA - Conference and earnings call announcements

SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week). During the week, Kazia will connect with existing and prospective institutional investors, sell-side analysts, and strategic collaborators, including both established partners and potential new industry counterparties, as part of ongoing investor relations and business development outreach. "We are entering JPM Week with strong strategic and clinical momentum," said Dr. John Friend, M.D., Chief Executive Officer of Kazia Therap

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are rising everywhere, but more dramatically in some places. According to a new analysis of CDC data, Maine currently has the highest rates among US states, while Utah has the lowest. However, another study found that survival rates for cancer patients on immunotherapy depend on their insurance coverage, whether it be through private, Medicaid, or those who are uninsured. With cases for several types of cancers, such as breast cancer, there is plenty of new tech innovation for diagnosis and treatments coming from the private sect

Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM) Company updates to corporate presentation and participation in upcoming medical meetings SYDNEY, Nov. 4, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting with the Company in December 2024 to discuss the potential pathways to registration of Kazia's blood brain barrier penetrant PI3K/mTOR inhibitor, paxalisib, for the treatment of patients with newly diagnosed GBM. In July 2024, the Company announced results from the Ph

Brain Cancers Forum on Glioblastoma & Diffuse Intrinsic Pontine Glioma Forum SYDNEY, May 25, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, has been invited to the White House to participate in the Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) & Diffuse Intrinsic Pontine Glioma (DIPG), to be held on Thursday, 25 May 2023.  In alignment with President Joe Biden and First Lady Dr. Jill Biden's commitment to end cancer, the forum will bring together patients, caregivers, oncologists, researchers

SYDNEY, Sept. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the upcoming 24th Annual Global Investment Conference, held in New York, NY, from 12 – 14 September 2022. Dr Garner's presentation will review three positive data read-outs that Kazia has reported so far in 2022 and will look ahead to some key developments that are anticipated over coming months. Representatives of the Kazia management team will be available to conduct o

SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer. Key Points Orphan Drug Designation (ODD) is a special status accorded to drugs which are considered promising potential treatments for rare ('orphan') diseases, generally defined as those which affect less than 200,000 cases per annum in the United States.ODD can provide drug developers with up to

SYDNEY, June 13, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the presentation of new data regarding the activity of paxalisib in two forms of childhood brain cancer with poor prognosis and limited treatment options. The data is the subject of two poster presentations at the 20th International Symposium on Pediatric Neuro-Oncology (ISPNO), held in Hamburg, Germany, from 12-15 June 2022. The first poster is presented by Dr Jeffrey Rubens at Johns Hopkins University and describes the activity of paxalisib in combination with a second drug in animal models of atypical teratoid / rhabdoid tumors (A

SYDNEY, May 23, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at two upcoming investor conferences. Dr Garner will present on behalf of Kazia at the HC Wainwright Global Investment Conference, to be held in person and virtually in Miami, FL, from 23-26 May 2022. The presentation will highlight some of the upcoming news flow that is anticipated from Kazia's broad ongoing clinical program, including abstracts at two international scientific conferences in June. Representatives of the Kazia management team will be available to conduct one-on-one meetin

SYDNEY, May 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), a late-stage, oncology-focused drug development company, marks 'DIPG Awareness Day' by recognizing the tireless work of global researchers in this disease, and by calling for an increased focus on childhood brain cancer among policymakers. Brain tumours represent the second most common group of cancers in children worldwide, after leukemia, but are the most common cause of cancer death. Around 10-15% of childhood brain cancers are diffuse midline gliomas (DMGs), a group that includes dif

SYDNEY, March 21, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), a late stage, oncology-focused drug development company, is pleased to announce upcoming presentations at two international conferences. American Association of Cancer Research Annual Scientific Meeting Four abstracts relating to Kazia's pipeline have been accepted for presentation at the upcoming American Association of Cancer Research (AACR) Annual Scientific Meeting, held in New Orleans, LA from 8th – 13th April 2022. Two abstracts relate to the ongoing phase I study of EVT801, a selective VEGFR3 inhibitor in development for advanced cancer. The other two pertain to paxalisib, a brain-penetrant P

SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the BIO CEO Conference, to be held in person and virtually in New York, NY, from 14-17 February 2022. Hosted annually by the Biotechnology Innovation Organization (BIO) for over 20 years, the conference is focused on emerging public and private companies, offering a meeting place for institutional investors, industry analysts, and senior biotech executives. The conference draws biotech companies looking to make the connections needed to take their products to the next phase.  Kazia will

SYDNEY, Jan. 25, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the Edison Group 'Open House' Event, to be held virtually from 25-27 January 2022. Kazia will be one of 33 leading healthcare companies to be featured at the three-day event, which is being held in association with London Stock Exchange, global law firm Taylor Wessing, and OpenExchange. Day one of the conference will feature businesses within pharmaceuticals and drug disco

SYDNEY, Jan. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from 10-13 January 2022. The company has been invited to participate via a 'fireside chat' with a senior equity research analyst at the bank. The HC Wainwright BioConnect Conference brings together more than 275 presenting companies from the life sciences sector, along with invited speakers and panellists. This year's keynote speakers include Scott Gottlieb, MD, who was Commissioner of the Food and Drug Administration (FDA) be

SYDNEY, Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be held virtually and in person from 12-14 October 2021. Since 2008, the LD Micro Main Event has established itself as one of the leading conferences for small-cap companies across a wide range of sectors. This year's event will see approximately 120 participating companies, with presentations over three days. The conference will be conducted in a hybrid format, with a virtual component and an in-person component at the Luxe Sunset Bel Air hotel in Los Angele

SYDNEY, Sept. 10, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annual Global Investment Conference, to be held virtually from 13-15 September 2021. The HC Wainwright Annual Global Investment Conference is one of the key events in the investor calendar and Kazia's participation comes at an important time for the company. Kazia's lead program, paxalisib, is currently in a pivotal study for glioblastoma, the most common and most aggressive form of brain cancer. If successful, paxalisib has the potential to become the first ne

SYDNEY, June 3, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, announced today that its CEO, Dr James Garner, will be presenting virtually at the upcoming LD Micro Invitational XI. Dr Garner commented, "this is a particularly exciting time for Kazia, with our lead program, paxalisib, now well-advanced in a pivotal study, and a promising new program, EVT801, due to enter the clinic this year. We look forward to updating the attendees on our progress, and on the rich slate of news flow anticipated for the second half

SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited ((ASX: KZA, NASDAQ:KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA: EVT), a leading European drug discovery and development company, for EVT801, a small-molecule, first-in-class oncology drug candidate. Kazia expects to launch a phase I clinical trial of EVT801 in CY2021. Key Points Evotec has granted Kazia an exclusive global worldwide license to develop, manufacture

SYDNEY, March 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA;NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (Simcere) (HKSE: 2096) to develop and commercialise Kazia's investigational new drug, paxalisib, in Greater China. Key Points Simcere will assume responsibility for the development, registration, and commercialisation of paxalisib in Greater China - a territory which includes Mainland China, Hong Kong, Macau, and Taiwan. Kazia retains rights to the development and commercialisation of paxalisib in all other territories and will continue to drive fo

LOS ANGELES--(BUSINESS WIRE)--Global Coalition for Adaptive Research (LOS ANGELES, CA), Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA, SYDNEY, Australia), and Kintara Therapeutics, Inc. (NASDAQ: KTRA, SAN DIEGO, CA) -- The Global Coalition for Adaptive Research (GCAR) in collaboration with Kazia and Kintara, today announced the activation of Kazia's paxalisib and Kintara's VAL-083 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – the deadliest form of brain cancer.